

Cuba will seek recognition of its anti-viral vaccines at WHO on Thursday

Image not found or type unknown



This was reported by a senior official of BioCubaFarma

Havana, Sep 15 (RHC) Cuba is getting ready for next Thursday's meeting with representatives of the World Health Organization (WHO) in which it will seek international recognition of the vaccines against coronavirus developed by the Caribbean country.

BioCubaFarma's Director of Science and Innovation, Rolando Pérez, said that after the next meeting, the WHO experts will begin to evaluate the documentation submitted on the anti-Covid-19 vaccines.

Previously, the representative of the Pan American and World Health Organization (PAHO/WHO) in Havana, José Moya, explained that a working team will be set up to review the results of the clinical trials, production processes and quality of the three Cuban vaccines against the coronavirus.

The Cuban vaccines Abdala, Soberana 02 and Soberana Plus were the first in Latin America to receive authorization from the national regulatory authorities for emergency use.

The Abdala vaccine, developed by the Center for Genetic Engineering and Biotechnology (CIGB), proved a 92.2 percent efficacy against coronavirus in its clinical trials.

Soberana 02 plus a booster of its counterpart Soberana Plus, both from the Finlay Vaccine Institute (IFV), showed 91.2 percent efficacy during clinical trials.

On several occasions, PAHO has recognized Cuba's efforts in the development of anti-Covid-19 vaccines and their importance for the region.

Cuban vaccines are already being used in some countries as part of bilateral agreements and collaboration in the development of clinical studies, while the immunization process with them is advancing throughout Cuba.

<https://www.radiohc.cu/index.php/en/noticias/nacionales/270302-cuba-will-look-for-recognition-of-its-anti-viral-vaccines-at-who-on-thursday>



Radio Habana Cuba